- Home
- JBHT vs RPRX Comparison
JBHT vs RPRX Comparison
Compare JBHT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBHT | RPRX |
|---|---|---|
| Founded | 1961 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 25.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JBHT | RPRX |
|---|---|---|
| Price | $227.20 | $57.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 8 |
| Target Price | ★ $298.00 | $65.13 |
| AVG Volume (30 Days) | 991.6K | ★ 2.7M |
| Earning Date | 10-15-2026 | 11-04-2026 |
| Dividend Yield | 0.80% | ★ 1.61% |
| EPS Growth | ★ 10.07 | N/A |
| EPS | ★ 3.39 | 0.71 |
| Revenue | ★ $7,189,568,000.00 | $2,378,193,000.00 |
| Revenue This Year | $14.33 | $47.32 |
| Revenue Next Year | $9.47 | $8.70 |
| P/E Ratio | ★ $67.34 | $82.08 |
| Revenue Growth | ★ 9.67 | 5.06 |
| 52 Week Low | $134.53 | $35.23 |
| 52 Week High | $299.76 | $64.38 |
Technical Indicators
Market Signals| Indicator | JBHT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 41.62 |
| Support Level | $212.47 | $57.75 |
| Resistance Level | $235.41 | $58.84 |
| Average True Range (ATR) | 6.42 | 1.07 |
| MACD | -1.88 | -0.12 |
| Stochastic Oscillator | 0.00 | 24.51 |
Price Performance
Historical ComparisonAbout JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.